Cele mai bune Oncology Times podcast-uri (2024)

1
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors 14:28

7d ago14:28

14:28

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO C…

1
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma 8:07

7d ago8:07

8:07

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding r…

1
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer 9:00

7d ago9:00

9:00

Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy.This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Pha…

1
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy 10:45

8d ago10:45

10:45

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024.Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patient…

1
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma 12:05

14d ago12:05

12:05

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multi…

1
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy 6:17

14d ago6:17

6:17

A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world’s biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included patients from clinical trials and real-world studies wh…

1
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer 10:01

23d ago10:01

10:01

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology In…

1
ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More 13:23

24d ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent, MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center in Singapore (with a special interest in all …

1
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood 13:04

24d ago13:04

13:04

The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China. At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 202…

1
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors 9:51

1M ago9:51

9:51

Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University. After his talk at CSCO, Dorigo told Oncol…

1
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment 8:43

1M ago8:43

8:43

An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development fo…

1
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting 8:21

1M ago8:21

8:21

At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that p…

1
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer 7:26

1M ago7:26

7:26

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncol…

1
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients 11:33

1M ago11:33

11:33

Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in…

1
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies 13:23

1M ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all asp…

1
HPV Vaccination Prevents HIV-Related Cancers in Men 6:02

4M ago6:02

6:02

HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated ca…

1
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought 4:31

4M ago4:31

4:31

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the st…

1
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers 6:28

4M ago6:28

6:28

Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.OncTimesTalk reporter Pete…

1
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia 7:39

4M ago7:39

7:39

A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of L…

1
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival 9:02

4M ago9:02

9:02

When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34…

1
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer 14:15

4M ago14:15

14:15

Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncT…

1
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes 10:53

4M ago10:53

10:53

The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of N…

1
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma 11:34

4M ago11:34

11:34

A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut…

1
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia 9:25

5M ago9:25

9:25

Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital,…

1
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma 6:52

5M ago6:52

6:52

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the…

1
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy 8:13

5M ago8:13

8:13

Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After a…

1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC 8:50

5M ago8:50

8:50

New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…

1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer 11:34

5M ago11:34

11:34

When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study r…

1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic 17:36

5M ago17:36

17:36

An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…

1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma 10:31

5M ago10:31

10:31

The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …

1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC 8:21

5M ago8:21

8:21

A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…

1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes 13:46

5M ago13:46

13:46

A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…

1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic 17:35

6M ago17:35

17:35

An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…

1
Exercise Deters Prostate Cancer Death & Progression 10:24

6M ago10:24

10:24

Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…

1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers 9:31

6M ago9:31

9:31

Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…

1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma 15:07

6M ago15:07

15:07

Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…

1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection 12:50

6M ago12:50

12:50

An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …

1
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers 13:00

6M ago13:00

13:00

Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in s…

1
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery 10:27

6M ago10:27

10:27

Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplina…

1
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed 8:38

6M ago8:38

8:38

The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable effi…

1
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain 15:40

6M ago15:40

15:40

A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The populatio…

1
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection 9:42

6M ago9:42

9:42

Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department …

1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema 34:36

7M ago34:36

34:36

Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …

1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes 8:47

7M ago8:47

8:47

New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…

1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer 9:00

7M ago9:00

9:00

Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…

1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer 9:35

7M ago9:35

9:35

Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …

1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab 15:44

7M ago15:44

15:44

About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…

1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia 20:15

8M ago20:15

20:15

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…

1
Important Mantle Cell Lymphoma Findings From the Sympatico Study 13:55

8M ago13:55

13:55

How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…

Podcasturi care merită ascultate

Oncology Times Podcast-uri

Podcasturi care merită ascultate

Ghid rapid de referință